Trial Profile

Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 08 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gartisertib (Primary) ; Niraparib (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions

Most Recent Events

06 Jun 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
28 Dec 2022 Planned End Date changed from 1 Dec 2027 to 1 May 2027.
28 Dec 2022 Planned primary completion date changed from 1 Dec 2023 to 1 May 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com